Studies on the mechanism of action of probucol - PubMed (original) (raw)
Studies on the mechanism of action of probucol
D Steinberg. Am J Cardiol. 1986.
Abstract
Earlier clinical studies suggested that probucol lowers plasma levels of low density lipoprotein (LDL) by increasing the rate of its removal. The drug has been shown to be effective in patients lacking the LDL receptor and, more recently, in LDL receptor-deficient rabbits. These latter studies showed that probucol increased the fractional catabolic rate of LDL by 40% to 50%. This finding in a receptor-deficient model implies that probucol can enhance the removal of LDL cholesterol by alternative pathways. Because the same enhanced removal was seen when LDL from probucol-treated rabbits was injected into untreated rabbits, it appears that the drug somehow alters the metabolic properties of the LDL itself rather than the metabolic behavior of the tissues of treated animals. Whether or not this mechanism explains the action of probucol in man remains to be determined. It has been postulated that the oxidative modification of LDL might contribute to atherogenesis by facilitating lipid accumulation in macrophages (foam cells) and by inhibiting macrophage motility. LDL resists oxidative modification, however, when probucol is added to in vitro incubations or when the LDL itself is isolated from probucol-treated patients. These findings lay the groundwork for evaluating the possible in vivo significance of LDL oxidation.
Similar articles
- In vivo inhibition of foam cell development by probucol in Watanabe rabbits.
Steinberg D, Parthasarathy S, Carew TE. Steinberg D, et al. Am J Cardiol. 1988 Jul 25;62(3):6B-12B. doi: 10.1016/s0002-9149(88)80044-4. Am J Cardiol. 1988. PMID: 3394654 - A novel mechanism by which probucol lowers low density lipoprotein levels demonstrated in the LDL receptor-deficient rabbit.
Naruszewicz M, Carew TE, Pittman RC, Witztum JL, Steinberg D. Naruszewicz M, et al. J Lipid Res. 1984 Nov;25(11):1206-13. J Lipid Res. 1984. PMID: 6520542 - Probucol inhibits oxidative modification of low density lipoprotein.
Parthasarathy S, Young SG, Witztum JL, Pittman RC, Steinberg D. Parthasarathy S, et al. J Clin Invest. 1986 Feb;77(2):641-4. doi: 10.1172/JCI112349. J Clin Invest. 1986. PMID: 3944273 Free PMC article. - Probucol: pharmacology and clinical application.
Zimetbaum P, Eder H, Frishman W. Zimetbaum P, et al. J Clin Pharmacol. 1990 Jan;30(1):3-9. doi: 10.1002/j.1552-4604.1990.tb03431.x. J Clin Pharmacol. 1990. PMID: 2406299 Review. - Role of biologically modified low-density lipoprotein in atherosclerosis.
Carew TE. Carew TE. Am J Cardiol. 1989 Oct 3;64(13):18G-22G. doi: 10.1016/0002-9149(89)90951-x. Am J Cardiol. 1989. PMID: 2679026 Review.
Cited by
- Probucol. A reappraisal of its pharmacological properties and therapeutic use in hypercholesterolaemia.
Buckley MM, Goa KL, Price AH, Brogden RN. Buckley MM, et al. Drugs. 1989 Jun;37(6):761-800. doi: 10.2165/00003495-198937060-00002. Drugs. 1989. PMID: 2667936 Review. - An overview of lipid-lowering drugs.
Illingworth DR. Illingworth DR. Drugs. 1988;36 Suppl 3:63-71. doi: 10.2165/00003495-198800363-00015. Drugs. 1988. PMID: 3076124 Review. - Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia.
Kita T, Nagano Y, Yokode M, Ishii K, Kume N, Ooshima A, Yoshida H, Kawai C. Kita T, et al. Proc Natl Acad Sci U S A. 1987 Aug;84(16):5928-31. doi: 10.1073/pnas.84.16.5928. Proc Natl Acad Sci U S A. 1987. PMID: 3475709 Free PMC article. - Paradoxical enhancement of atherosclerosis by probucol treatment in apolipoprotein E-deficient mice.
Zhang SH, Reddick RL, Avdievich E, Surles LK, Jones RG, Reynolds JB, Quarfordt SH, Maeda N. Zhang SH, et al. J Clin Invest. 1997 Jun 15;99(12):2858-66. doi: 10.1172/JCI119479. J Clin Invest. 1997. PMID: 9185508 Free PMC article. - Probucol attenuates the development of aortic atherosclerosis in cholesterol-fed rabbits.
Daugherty A, Zweifel BS, Schonfeld G. Daugherty A, et al. Br J Pharmacol. 1989 Oct;98(2):612-8. doi: 10.1111/j.1476-5381.1989.tb12635.x. Br J Pharmacol. 1989. PMID: 2819336 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical